Explore Our Biomarker Menu

Biological or Clinical Significance:

Macrophage-Derived Chemokine (MDC; CCL22) is expressed highly in macrophages and in monocyte-derived dendritic cells. High expression is detected in normal thymus and lower expression in lung and spleen. MDC is expressed by a subset of macrophages within regions of advanced atherosclerotic plaques that contain plaque micro-vessels. MDC is a potent chemoattractant for neutrophilic granulocytes, enhancing their bactericidal activity and stimulating the release of lysozyme.

The protein encoded by this gene is secreted by dendritic cells and macrophages, and elicits its effects on its target cells by interacting with cell surface chemokine receptors such as CCR4.[4] The gene for CCL22 is located in human chromosome 16 in a cluster with other chemokines called CX3CL1 and CCL17.

References:

Analyte:

CCL22

Matrix:

Human Serum

Status:

Experienced Running

Sensitivity-LLOQ:

0.68 pg/mL

Sensitivity-ULOQ:

platform

Ella

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.